Literature DB >> 17919820

Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients.

P Boorboor1, P M Vogt, F G Bechara, Q Alkandari, M Aust, A Gohritz, M Spies.   

Abstract

INTRODUCTION: Toxic epidermal necrolysis is a rare disease with high mortality due to generalised infection, sepsis or lung involvement, and requires discontinuation of all potentially triggering medications and intensive care in a specialised burn centre. Apart from wound care with antiseptics, wound coverage may be achieved with a skin substitute; treatments are compared with regard to infection, protein loss, re-epithelialisation and mortality. PATIENTS AND METHODS: Of 14 people with toxic epidermal necrolysis affecting >30% body surface area, eight received daily dressing changes using Lavasept nd six received wound coverage with Biobrane. Demographic data, SCORTEN score, mortality, visual-analog pain scale, mobilisation, time to re-epithelialisation, serum protein, albumin, C-reactive protein and leukocytes, and body temperature were evaluated in all cases.
RESULTS: Mean age of patients was 68.0+/-14.8 years, mean body surface area affected was 66.4%, median SCORTEN score was three and overall mortality was 36%. In the Biobrane ompared with the Lavasept control) group, mean pain was significantly reduced (2.9 versus 5.5 on the scale, p<0.05), mobilisation was significantly earlier (walking at 3 days versus 7 days, p=0.003), re-epithelialisation was complete in 12.5 days versus 16 days, and at 9 days there was reduced decrease of serum proteins and significantly lower levels of C-reactive protein and white cells (p<0.05).
CONCLUSION: Early wound coverage with synthetic skin substitute such as Biobrane s beneficial compared with conservative antiseptic wound treatment, but mortality rate is not significantly different.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919820     DOI: 10.1016/j.burns.2007.06.008

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  8 in total

Review 1.  Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Authors:  Olivia A Charlton; Victoria Harris; Kevin Phan; Erin Mewton; Chris Jackson; Alan Cooper
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-09       Impact factor: 4.730

Review 2.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

3. 

Authors:  A Mokline; I Rahmani; L Garsallah; S Tlaili; R Hammouda; A A Messadi
Journal:  Ann Burns Fire Disasters       Date:  2016-03-31

4.  Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality.

Authors:  Jean-Claude Roujeau; Sylvie Bastuji-Garin
Journal:  Ther Adv Drug Saf       Date:  2011-06

5.  A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virus.

Authors:  Gerrit Grieb; Mastoura Alazemi; Rituparna Das; Sebastian E Dunda; Paul C Fuchs; Norbert Pallua
Journal:  Case Rep Dermatol       Date:  2010-12-07

6.  Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer.

Authors:  Mozaffar Aznab; Mansour Khazaei
Journal:  Iran J Cancer Prev       Date:  2016-06-13

7.  Case Report: Wound Closure Acceleration in a Patient With Toxic Epidermal Necrolysis Using a Lyophilised Amniotic Membrane.

Authors:  Bretislav Lipový; Martin Hladík; Petr Štourač; Serhiy Forostyak
Journal:  Front Bioeng Biotechnol       Date:  2021-04-16

8.  Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins).

Authors:  Saskia Ingen-Housz-Oro; Tu-Anh Duong; Benoit Bensaid; Nathalia Bellon; Nicolas de Prost; Dévy Lu; Bénédicte Lebrun-Vignes; Julie Gueudry; Emilie Bequignon; Karim Zaghbib; Gérard Royer; Audrey Colin; Giao Do-Pham; Christine Bodemer; Nicolas Ortonne; Annick Barbaud; Laurence Fardet; Olivier Chosidow; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.